322 related articles for article (PubMed ID: 26721330)
1. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial.
Jamshed S; Walsh EE; Dimitroff LJ; Santelli JS; Falsey AR
Vaccine; 2016 Jan; 34(5):630-635. PubMed ID: 26721330
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.
Falsey AR; Treanor JJ; Tornieporth N; Capellan J; Gorse GJ
J Infect Dis; 2009 Jul; 200(2):172-80. PubMed ID: 19508159
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
Tsang P; Gorse GJ; Strout CB; Sperling M; Greenberg DP; Ozol-Godfrey A; DiazGranados C; Landolfi V
Vaccine; 2014 May; 32(21):2507-17. PubMed ID: 24120672
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.
DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
Vaccine; 2015 Aug; 33(36):4565-71. PubMed ID: 26187260
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK
N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
9. Randomized Double-Blind Study of the Safety and Immunogenicity of Standard-Dose Trivalent Inactivated Influenza Vaccine versus High-Dose Trivalent Inactivated Influenza Vaccine in Adult Hematopoietic Stem Cell Transplantation Patients.
Halasa NB; Savani BN; Asokan I; Kassim A; Simons R; Summers C; Bourgeois J; Clifton C; Vaughan LA; Lucid C; Wang L; Fonnesbeck C; Jagasia M
Biol Blood Marrow Transplant; 2016 Mar; 22(3):528-35. PubMed ID: 26705931
[TBL] [Abstract][Full Text] [Related]
10. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season.
DiazGranados CA; Dunning AJ; Jordanov E; Landolfi V; Denis M; Talbot HK
Vaccine; 2013 Jan; 31(6):861-6. PubMed ID: 23261045
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
Greenberg DP; Robertson CA; Noss MJ; Blatter MM; Biedenbender R; Decker MD
Vaccine; 2013 Jan; 31(5):770-6. PubMed ID: 23228813
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety assessment of a trivalent, inactivated split influenza vaccine in Korean children: Double-blind, randomized, active-controlled multicenter phase III clinical trial.
Han SB; Rhim JW; Shin HJ; Lee SY; Kim HH; Kim JH; Lee KY; Ma SH; Park JS; Kim HM; Kim CS; Kim DH; Choi YY; Cha SH; Hong YJ; Kang JH
Hum Vaccin Immunother; 2015; 11(5):1094-102. PubMed ID: 25875868
[TBL] [Abstract][Full Text] [Related]
15. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection.
Hakim H; Allison KJ; Van de Velde LA; Tang L; Sun Y; Flynn PM; McCullers JA
Vaccine; 2016 Jun; 34(27):3141-3148. PubMed ID: 27129426
[TBL] [Abstract][Full Text] [Related]
19. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
Lambkin-Williams R; Gelder C; Broughton R; Mallett CP; Gilbert AS; Mann A; He D; Oxford JS; Burt D
PLoS One; 2016; 11(12):e0163089. PubMed ID: 28005959
[TBL] [Abstract][Full Text] [Related]
20. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
